Applied DNA Sciences超出第三季度每股收益预期1.11美元，但未能实现收入目标，导致股价上涨和分析师评级喜忧参半。 Applied DNA Sciences exceeded Q3 EPS estimates by $1.11, but missed revenue targets, leading to stock price increase and mixed analyst ratings.
应用DNA科学(APDN)报告,Q3收入为0.47 EPS,超过分析师协商一致估计的1.11美元。 Applied DNA Sciences (APDN) reported Q3 earnings of $0.47 EPS, exceeding analysts' consensus estimates by $1.11. 尽管产生了0.80亿美元的收入,低于预计的0.95亿美元,但该公司的股票价格上涨了0.1美元,达到0.36美元。 Despite generating $0.80M in revenue, falling short of the projected $0.95M, the firm's stock price increased by $0.01, reaching $0.36. 华因赖特公司将目标价降至1.50美元, 保持"买入"评级, 而StockNews.com则发布"卖出"评级. HC Wainwright lowered their target price to $1.50 while maintaining a "buy" rating, while StockNews.com issued a "sell" rating. APDN在DNA生产、检测服务和DNA标记以及安全产品和服务方面运作。 APDN operates in DNA production, testing services, and DNA tagging and security products and services.